BRAF inhibitors in metastatic non-small cell lung cancer

Lung cancer is the first cause of death by cancer in men and the second in women worldwide (1). This huge mortality is explained by the presence of advanced disease at diagnosis of lung cancer (78% of patients present locoregional and/or distant metastasis). Non-small cell lung cancer (NSCLC) represents up to 85% of all lung cancers (2), with a 5-year overall survival about 17% (3).